News for CSL Limited (CMXHF)

Published at

Jul 25, 2025 12:00 AM

by gurufocus.com

positive

positive

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Arcturus Therapeutics Holdings Inc. (the ”Company”, ”Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

CSLLY CMXHF ARCT

Read more →
Published at

Jul 24, 2025 12:00 AM

by gurufocus.com

positive

positive

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Arcturus Therapeutics Holdings Inc. (the ”Company”, ”Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

CSLLY CMXHF ARCT

Read more →
Published at

Jul 8, 2025 2:57 AM

by raskmedia.com.au

positive

positive

Is WiseTech Global (ASX:WTC) the ASX’s next CBA?

Why WiseTech Global (ASX:WTC) could be the next blue chip in the Australian market and what to watch out for.

WTC.AX CSLN.MX CSLLY CSL.AX CMXHF CMWAY CBAUF CBAPJ.AX CBA.AX BIL.DE BHPN.MX BHPLF BHPBF BHP.L BHP.JO BHP.BA BHP.AX BHP BBL B1BL34.SA AND.AX 0HN3.L

Read more →
Published at

Jul 1, 2025 8:51 AM

by raskmedia.com.au

mixed

mixed

Pearler writes: ASX 200 vs S&P 500

How do ASX 200 and S&P 500 funds stack up? Discover the differences and learn how to choose the right option for your portfolio.

TLS.AX SKJJF GOOGL CMWAY CBAUF CBAPJ.AX CBA.AX BIL.DE BHPN.MX BHPLF BHPBF BHP.L BHP.JO BHP.BA BHP.AX BHP BBL B1BL34.SA 0KZC.L 0HN3.L WEBNF WBK.BA WBK WBC.NZ WBC.AX W1BK34.SA JNJ DJNJ3.BA DJNJ2.BA CSLN.MX CSLLY CSL.AX CMXHF 0LVV.L WOW.AX

Read more →
Published at

Jun 26, 2025 10:55 PM

by gurufocus.com

positive

positive

Valneva (VALN) Partners with CSL to Boost Vaccine Sales in Germany

Key Takeaways: Valneva SE partners with CSL Limited to boost vaccine distribution in Germany. Analysts predict a significant upside for Valneva SE stock.

VLA.PA INRLF CSLN.MX CSLLY CSL.AX CMXHF 0OB3.L

Read more →
Published at

Jun 23, 2025 4:00 PM

by gurufocus.com

positive

positive

Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency

Arcturus Therapeutics Holdings Inc. (the ”Company”, ”Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

CSLLY CMXHF ARCT

Read more →
Published at

May 30, 2025 12:00 AM

by gurufocus.com

positive

positive

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Arcturus Therapeutics Holdings Inc. (the ”Company”, ”Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development o

CSLLY CMXHF ARCT

Read more →
Published at

May 14, 2025 2:15 PM

by gurufocus.com

mixed

mixed

Wells Fargo Adjusts Price Target for Arcturus Therapeutics (ARCT) | ARCT Stock News

Wells Fargo has revised its price target for Arcturus Therapeutics (ARCT), lowering it from $50 to $45, while maintaining an Overweight rating on the shares. Th

CSLLY CMXHF ARCT

Read more →
Published at

May 13, 2025 9:10 AM

by gurufocus.com

mixed

mixed

Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call Highlights: Strategic Focus and Financial Resilience Amid Revenue Decline

Revenue: $29.4 million for Q1 2025, down from $38 million in Q1 2024.Research and Development Expenses: $34.9 million for Q1 2025, down from $53.6 million in Q

CSLLY CMXHF ARCT

Read more →
Published at

May 13, 2025 12:00 AM

by gurufocus.com

positive

positive

Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress

Arcturus Therapeutics Holdings Inc. (the ”Company”, ”Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

CSLLY CMXHF ARCT

Read more →
Published at

May 12, 2025 11:20 PM

by gurufocus.com

mixed

mixed

Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings: EPS of ($0.52) Beats Estimate, Revenue of $29.4M Surpasses Expectations

Revenue: $29.4 million for Q1 2025, surpassing the estimated $27.88 million, but down from $38.0 million in Q1 2024 due to lower milestone revenues.Net Loss: $

CSLLY CMXHF ARCT

Read more →
Published at

Apr 23, 2025 12:00 AM

by gurufocus.com

positive

positive

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

Arcturus Therapeutics Holdings Inc. (the ”Company”, ”Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

CSLLY CMXHF ARCT

Read more →
Published at

Apr 10, 2025 4:00 PM

by gurufocus.com

positive

positive

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

Arcturus Therapeutics Holdings Inc. (the ”Company”, ”Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development o

CSLLY CMXHF ARCT

Read more →
Published at

Apr 9, 2025 11:10 PM

by raskmedia.com.au

mixed

mixed

S&P 500 rockets 9% overnight not to be outdone by the Nasdaq up 11%

S&P 500 and Nasdaq rebound 9% and 11% respectively. Australian pharmaceuticals, CSL Limited look to rebound strongly.

MIN.AX MALRY MALRF NEU.AX MSB.AX MESO MEOBF CSLN.MX CSLLY CSL.AX CMXHF

Read more →
Published at

Mar 7, 2025 8:17 AM

by gurufocus.com

mixed

mixed

Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating Challenges with Strategic Advances

Revenue (FY 2024): $152.3 million, a decrease from $166.8 million in 2023.Revenue (Q4 2024): $22.8 million, down from $30.9 million in Q4 2023.Net Loss (FY 202

ARCT CSLLY CMXHF

Read more →
Published at

Mar 3, 2025 2:00 PM

by gurufocus.com

positive

positive

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

”“ Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales ”“ ANN ARBOR, Mich., March 03, 2

ESPR CSLN.MX CSLLY CSL.AX CMXHF 0IIM.L

Read more →
Published at

Feb 24, 2025 11:00 PM

by gurufocus.com

positive

positive

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

Arcturus Therapeutics Holdings Inc. (the ”Company”, ”Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

CSLLY CMXHF ARCT

Read more →
Published at

Feb 14, 2025 3:00 PM

by gurufocus.com

mixed

mixed

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

PR NewswireWALTHAM, Mass. and SAN DIEGO, Feb. 14, 2025 - KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immuno

VTG.AX SFFYF PHPPY CSLLY CSL.AX CMXHF ASXFY ASXFF ARCT TGA.AX

Read more →
Published at

Feb 14, 2025 3:00 PM

by gurufocus.com

mixed

mixed

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission

VTG.AX SFFYF PHPPY CSLLY CSL.AX CMXHF ASXFY ASXFF ARCT

Read more →
Published at

Feb 11, 2025 8:17 PM

by forbes.com

neutral

neutral

Inside Takeda’s Plasma-Derived Therapy Ecosystem

Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, a key revenue driver at $5.85B in 2023.

CSLN.MX CSLLY CSL.AX CMXHF

Read more →